ELAN Investment Buzz – What's Driving the Interest?

By Tamara Parker • Wednesday, May 14 10:08 • Permanent Link

Join us for a quick overview of Elanco Animal Health, a Pharmaceutical company whose shares moved -1.8% today. Here are some facts about the stock that should help you see the bigger picture:

Elanco Animal Health has moved -23.6% over the last year, and the S&P 500 logged a change of 10.9%
ELAN has an average analyst rating of buy and is -9.85% away from its mean target price of $14.18 per share
Its trailing earnings per share (EPS) is $0.75
Elanco Animal Health has a trailing 12 month Price to Earnings (P/E) ratio of 17.0 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $0.94 and its forward P/E ratio is 13.6
The company has a Price to Book (P/B) ratio of 1.0 in contrast to the S&P 500's average ratio of 4.74
Elanco Animal Health is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
ELAN has reported YOY quarterly earnings growth of 116.7% and gross profit margins of 0.5%
The company has a free cash flow of $1.32 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.